The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2 (Small 39/2024)

Goeun Choi,N. Sanoj Rejinold,Huiyan Piao,Young Bae Ryu,Hyung‐Jun Kwon,In Chul Lee,Jeong In Seo,Hye Hyun Yoo,Geun‐woo Jin,Jin‐Ho Choy
DOI: https://doi.org/10.1002/smll.202470291
IF: 13.3
2024-09-27
Small
Abstract:COVID‐19 Antiviral The global need for next generation antivirals due to SARS‐CoV‐2 mutations led to interest in niclosamide, a broad spectrum antiviral. XAFTY is a niclosamide‐inorganic nanohybrid drug proven for its broad‐spectrum antiviral activity, overcoming niclosamide's low bioavailability. It has been confirmed in animal models to reduce SARS‐CoV‐2 viral load and prevent infection‐induced lung inflammation, and its safety was confirmed in the clinical trials. More in article number 2305148, Geun‐woo Jin, Jin‐Ho Choy, and co‐workers.
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
What problem does this paper attempt to address?